Earnings Call Intelligence Subscribe
Home › Call Sheets › IQV › Q2'26
Call sheet · Q2'26

IQVIA Holdings (IQV)

Q2'26 earnings call · held July 28, 2026 · compared with the Q1'26 call · management-credibility review
10/12
Disclosure score
1 medium, 5 low flags
Financial quality
Bottom line
The sleeper story is large pharma explicitly asking IQVIA to add thousands of FCEs because AI discovery will double their molecule pipelines; this isn't speculative demand, it's clients pre-committing capacity. Yes, they beat and raised, but the binding constraint remains large pharma decision velocity still below 'cruising altitude' despite $35B in EBP funding. Most revealing quote: 'Some of our large pharma clients are predicting they will double their study portfolio.' My view changes if Q3 bookings fall below $2.8B or if large pharma decision velocity doesn't improve by year-end.

The 30-second version

  • The real story: Large pharma asking IQVIA to add thousands of FCEs as AI-driven discovery doubles their molecule pipelines
  • Beat-and-raise quarter masks the binding constraint: Decision velocity still 'slower than cruising altitude' despite funding at $35B
  • Management stopped disclosing pass-through percentages after making them the scapegoat for Q1's weak book-to-bill

What changed this quarter

MetricQ1'26Q2'26Change
Total Revenue$4,151M (8.4% YoY)$4,368M (8.7% YoY)+30 bps growth acceleration
Organic Revenue Growth4.0% YoY6.0% YoY+200 bps acceleration, 3x last year's rate
Adjusted EBITDA$932M (5.5% YoY)$994M (9.2% YoY)+370 bps growth acceleration
Adjusted EPS$2.90 (7.4% YoY)$3.15 (12.1% YoY)+470 bps growth acceleration
R&DS Revenue$2,397M (6.2% YoY)$2,575M (8.8% YoY)+260 bps acceleration
R&DS Organic Growth3.0% YoY7.0% YoY+400 bps acceleration
Commercial Solutions Revenue$1,754M (11.6% YoY)$1,793M (8.6% YoY)-300 bps deceleration but comping tough Q1
Commercial Organic Growth5.0% YoY5.0% YoYSustained at double prior year rate
Net New Bookings$2.5B (10% YoY)$3.15B (19% YoY)+27% sequential surge
Book-to-Bill1.04x1.22x+18 points despite 9% revenue growth

Accountability tracked

6 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full IQV Q2'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.